LevodopaAntiparkinson AgentsCarbidopaParkinson DiseaseBenserazideDyskinesia, Drug-InducedDihydroxyphenylalanineTrihexyphenidylAdministration, OralDopamine AgentsDyskinesiasSelegilineDopamine AgonistsBromocriptineApomorphineBenzophenonesLisurideDrug Administration ScheduleParkinson Disease, SecondaryParkinson Disease, PostencephaliticDose-Response Relationship, DrugSubthalamic NucleusDopa DecarboxylaseMovement DisordersParkinsonian DisordersErgolinesInjections, IntravenousDystoniaTime FactorsMuscle RigidityDopamineDeep Brain StimulationUnited States Food and Drug AdministrationRats, Sprague-DawleyMotor SkillsTremorDouble-Blind MethodCatechol O-MethyltransferaseDrug CombinationsReceptors, DopamineDrug Administration RoutesAkinetic MutismBiological AvailabilityHydrazinesDrug Therapy, CombinationBenzothiazolesInjections, IntraperitonealRats, WistarAmantadineHalf-LifeDrug InteractionsDisease Models, AnimalMonoamine Oxidase InhibitorsGlobus PallidusNeurologic ExaminationInjections, SubcutaneousTreatment OutcomeAdministration, IntranasalCross-Over StudiesMucunaBrainDelayed-Action PreparationsMethyldopaGastric EmptyingBis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfideMotor Skills DisordersNeurologic ManifestationsOrphenadrineInfusions, IntravenousOxidopamineSalsoline AlkaloidsElectric Stimulation TherapyMotor Activity